Walleye Trading’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Walleye Trading’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6,100	Closed	-$14K	–	5880
2022 Q1	$14K	Sell	6,100 -158,400	-96%	-$494K	﹤0.01%	4862
2021 Q4	$765K	Sell	164,500 -66,500	-29%	-$413K	﹤0.01%	2507
2021 Q3	$1.76M	Buy	231,000 +219,200	+1,858%	+$1.86M	0.01%	1718
2021 Q2	$114K	Buy	+11,800	New	+$94K	﹤0.01%	4327

Other funds holding SRNE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Walleye Trading's SRNE Position: Q2 2022 in Review

Walleye Trading sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2022, closing a stake of 21,936 shares — an estimated $51K sold.

Walleye Trading first reported a position in SRNE in Q2 2015 and held it in 6 quarters. The position peaked at $979K in Q3 2021. 229 funds tracked by Wall St. Rank hold SRNE as of Q2 2022.

Walleye Trading reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
Walleye Trading sold 21,936 Sorrento Therapeutics, Inc. shares in Q2 2022, an estimated $51K.
Walleye Trading first reported a position in Sorrento Therapeutics, Inc. in Q2 2015 and held it in 6 quarters.
Walleye Trading's Sorrento Therapeutics, Inc. position peaked at $979K in Q3 2021.
229 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2022.

Based on Walleye Trading's 13F filing for Q2 2022, filed 8 Aug 2022.